Effects of different doses of atorvastatin on inflammation and clotting factors in patients with acute coronary syndrome after interventional treatment

Objective To evaluate the effects of atorvastatin(40 mg/d) on inflammation and clotting factors in acute coronary syndrome(ACS) patients after percutaneous coronary intervention(PCI) treatment.Methods A total of 100 patients with ACS were enrolled and assigned into 2 groups:Group A(conventional treatment group),in which 50 patients were treated with atorvastatin of 20 mg/d;Group B(intensive treatment group),50 patients received atorvastatin of 40 mg/d.Continuous drug treatment was given before PCI,until 1 month after the procedure.Blood samples were collected before PCI,and 5 and 30 days after PCI.Results(1) Significant increases of hs-CRP were revealed in both groups 5 days after PCI(P0.01),with significantly more prominence in Group A(P0.01).However,significant reductions of hs-CRP were revealed in both groups 30 days after PCI,with significantly more prominence in Group B(P0.01).(2) Although significant increase of TF was observed 5 days after PCI in Group A(P0.01),it returned to baseline level 30 days after PCI.No significant change of TF was observed in Group B 5 days after PCI(P0.05).Furthermore,significant reduction of TF was revealed 30 days after PCI(P0.01).(3) Although significant increase of TFPI was observed 5 days after PCI in Group A(P0.01),it returned to baseline level 30 days after PCI.No significant change of TFPI was observed in Group B 5 days after PCI(P0.05),furthermore,significant increase of TF was revealed 30 days after PCI(P0.01).Conclusion Atorvastatin(40 mg/d) effectively suppresses the inflammatory responses and balances TF/TFPI system in patients with ACS.